C M Parrinello1, K Matsushita1, M Woodward1,2,3, L E Wagenknecht4, J Coresh1,5, E Selvin1,5. 1. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Nuffield Department of Population Health, George Institute for Global Health, University of Oxford, Oxford, UK. 3. George Institute for Global Health, University of Sydney, Sydney, Australia. 4. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Department of Medicine, Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD, USA.
Abstract
AIMS: To develop a prediction equation for 10-year risk of a combined endpoint (incident coronary heart disease, stroke, heart failure, chronic kidney disease, lower extremity hospitalizations) in people with diabetes, using demographic and clinical information, and a panel of traditional and non-traditional biomarkers. METHODS: We included in the study 654 participants in the Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study, with diagnosed diabetes (visit 2; 1990-1992). Models included self-reported variables (Model 1), clinical measurements (Model 2), and glycated haemoglobin (Model 3). Model 4 tested the addition of 12 blood-based biomarkers. We compared models using prediction and discrimination statistics. RESULTS: Successive stages of model development improved risk prediction. The C-statistics (95% confidence intervals) of models 1, 2, and 3 were 0.667 (0.64, 0.70), 0.683 (0.65, 0.71), and 0.694 (0.66, 0.72), respectively (p < 0.05 for differences). The addition of three traditional and non-traditional biomarkers [β-2 microglobulin, creatinine-based estimated glomerular filtration rate (eGFR), and cystatin C-based eGFR] to Model 3 significantly improved discrimination (C-statistic = 0.716; p = 0.003) and accuracy of 10-year risk prediction for major complications in people with diabetes (midpoint percentiles of lowest and highest deciles of predicted risk changed from 18-68% to 12-87%). CONCLUSIONS: These biomarkers, particularly those of kidney filtration, may help distinguish between people at low versus high risk of long-term major complications.
AIMS: To develop a prediction equation for 10-year risk of a combined endpoint (incident coronary heart disease, stroke, heart failure, chronic kidney disease, lower extremity hospitalizations) in people with diabetes, using demographic and clinical information, and a panel of traditional and non-traditional biomarkers. METHODS: We included in the study 654 participants in the Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study, with diagnosed diabetes (visit 2; 1990-1992). Models included self-reported variables (Model 1), clinical measurements (Model 2), and glycated haemoglobin (Model 3). Model 4 tested the addition of 12 blood-based biomarkers. We compared models using prediction and discrimination statistics. RESULTS: Successive stages of model development improved risk prediction. The C-statistics (95% confidence intervals) of models 1, 2, and 3 were 0.667 (0.64, 0.70), 0.683 (0.65, 0.71), and 0.694 (0.66, 0.72), respectively (p < 0.05 for differences). The addition of three traditional and non-traditional biomarkers [β-2 microglobulin, creatinine-based estimated glomerular filtration rate (eGFR), and cystatin C-based eGFR] to Model 3 significantly improved discrimination (C-statistic = 0.716; p = 0.003) and accuracy of 10-year risk prediction for major complications in people with diabetes (midpoint percentiles of lowest and highest deciles of predicted risk changed from 18-68% to 12-87%). CONCLUSIONS: These biomarkers, particularly those of kidney filtration, may help distinguish between people at low versus high risk of long-term major complications.
Authors: Diewertje Sluik; Joline W J Beulens; Cornelia Weikert; Susan van Dieren; Annemieke M W Spijkerman; Daphne L van der A; Andreas Fritsche; Hans-Georg Joost; Heiner Boeing; Ute Nöthlings Journal: Diabetes Metab Res Rev Date: 2012-03 Impact factor: 4.876
Authors: Margaret S Pepe; Ziding Feng; Ying Huang; Gary Longton; Ross Prentice; Ian M Thompson; Yingye Zheng Journal: Am J Epidemiol Date: 2007-11-02 Impact factor: 4.897
Authors: Emanuele Di Angelantonio; Stephen Kaptoge; David Wormser; Peter Willeit; Adam S Butterworth; Narinder Bansal; Linda M O'Keeffe; Pei Gao; Angela M Wood; Stephen Burgess; Daniel F Freitag; Lisa Pennells; Sanne A Peters; Carole L Hart; Lise Lund Håheim; Richard F Gillum; Børge G Nordestgaard; Bruce M Psaty; Bu B Yeap; Matthew W Knuiman; Paul J Nietert; Jussi Kauhanen; Jukka T Salonen; Lewis H Kuller; Leon A Simons; Yvonne T van der Schouw; Elizabeth Barrett-Connor; Randi Selmer; Carlos J Crespo; Beatriz Rodriguez; W M Monique Verschuren; Veikko Salomaa; Kurt Svärdsudd; Pim van der Harst; Cecilia Björkelund; Lars Wilhelmsen; Robert B Wallace; Hermann Brenner; Philippe Amouyel; Elizabeth L M Barr; Hiroyasu Iso; Altan Onat; Maurizio Trevisan; Ralph B D'Agostino; Cyrus Cooper; Maryam Kavousi; Lennart Welin; Ronan Roussel; Frank B Hu; Shinichi Sato; Karina W Davidson; Barbara V Howard; Maarten J G Leening; Maarten Leening; Annika Rosengren; Marcus Dörr; Dorly J H Deeg; Stefan Kiechl; Coen D A Stehouwer; Aulikki Nissinen; Simona Giampaoli; Chiara Donfrancesco; Daan Kromhout; Jackie F Price; Annette Peters; Tom W Meade; Edoardo Casiglia; Debbie A Lawlor; John Gallacher; Dorothea Nagel; Oscar H Franco; Gerd Assmann; Gilles R Dagenais; J Wouter Jukema; Johan Sundström; Mark Woodward; Eric J Brunner; Kay-Tee Khaw; Nicholas J Wareham; Eric A Whitsel; Inger Njølstad; Bo Hedblad; Sylvia Wassertheil-Smoller; Gunnar Engström; Wayne D Rosamond; Elizabeth Selvin; Naveed Sattar; Simon G Thompson; John Danesh Journal: JAMA Date: 2015-07-07 Impact factor: 56.272
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Emanuele Di Angelantonio; Pei Gao; Hassan Khan; Adam S Butterworth; David Wormser; Stephen Kaptoge; Sreenivasa Rao Kondapally Seshasai; Alex Thompson; Nadeem Sarwar; Peter Willeit; Paul M Ridker; Elizabeth L M Barr; Kay-Tee Khaw; Bruce M Psaty; Hermann Brenner; Beverley Balkau; Jacqueline M Dekker; Debbie A Lawlor; Makoto Daimon; Johann Willeit; Inger Njølstad; Aulikki Nissinen; Eric J Brunner; Lewis H Kuller; Jackie F Price; Johan Sundström; Matthew W Knuiman; Edith J M Feskens; W M M Verschuren; Nicholas Wald; Stephan J L Bakker; Peter H Whincup; Ian Ford; Uri Goldbourt; Agustín Gómez-de-la-Cámara; John Gallacher; Leon A Simons; Annika Rosengren; Susan E Sutherland; Cecilia Björkelund; Dan G Blazer; Sylvia Wassertheil-Smoller; Altan Onat; Alejandro Marín Ibañez; Edoardo Casiglia; J Wouter Jukema; Lara M Simpson; Simona Giampaoli; Børge G Nordestgaard; Randi Selmer; Patrik Wennberg; Jussi Kauhanen; Jukka T Salonen; Rachel Dankner; Elizabeth Barrett-Connor; Maryam Kavousi; Vilmundur Gudnason; Denis Evans; Robert B Wallace; Mary Cushman; Ralph B D'Agostino; Jason G Umans; Yutaka Kiyohara; Hidaeki Nakagawa; Shinichi Sato; Richard F Gillum; Aaron R Folsom; Yvonne T van der Schouw; Karel G Moons; Simon J Griffin; Naveed Sattar; Nicholas J Wareham; Elizabeth Selvin; Simon G Thompson; John Danesh Journal: JAMA Date: 2014-03-26 Impact factor: 56.272
Authors: Caitlin W Hicks; Dan Wang; Natalie R Daya; B Gwen Windham; Christie M Ballantyne; Kunihiro Matsushita; Elizabeth Selvin Journal: Clin Chem Date: 2020-05-01 Impact factor: 8.327
Authors: Mohammad Ziaul Islam Chowdhury; Fahmida Yeasmin; Doreen M Rabi; Paul E Ronksley; Tanvir C Turin Journal: BMJ Open Date: 2019-08-30 Impact factor: 2.692